| GILD |
Report |
Q2 2026 total revenue |
BEAT |
pred ~$7.49B vs. cons $7.40B |
MEDIUM |
| GILD |
Report |
Q2 2026 Yeztugo sales |
BEAT |
pred ~$245M vs. cons $225M |
MEDIUM |
| GILD |
Report |
Q2 2026 Biktarvy sales |
BEAT |
pred ~$3.76B vs. cons $3.70B |
MEDIUM |
| GILD |
Guide |
FY2026 total product-sales guidance midpoint |
BETTER |
guide ~$30.4B vs. cons $30.3B (FY2026) |
MEDIUM |
| GILD |
Guide |
FY2026 Yeztugo sales guidance |
BETTER |
guide ~$1.10B vs. cons $1.05B (FY2026) |
MEDIUM |
| GILD |
Guide |
FY2026 underlying non-GAAP EPS excluding transaction effects |
LOWER |
guide ~$8.65 vs. cons $8.75 (FY2026) |
MEDIUM |
| GILD |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| GILD |
Return |
5-day cumulative residual |
+1.1% (FADE) |
Initial upside from Yeztugo, Biktarvy and the product-sales raise fades as unchanged underlying EPS guidance versus ~$8.75 consensus implies higher second-half launch and acquired-pipeline spending; the predicted 5-day residual is ~+1.1% versus a ~+2.5% day-1 residual. |
MEDIUM |